Clinical and pathogenetic substantiation of the use of Wobenzim in the complex treatment of generalized periodontitis.

Abstract

The purpose of this study was to determine the efficacy of using Wobenzim as a general therapy in the complex treatment of generalized periodontitis. 61 patients, I-II degree of severity, with tooth safety in an amount of at least 90%, without concomitant general pathology requiring treatment for the current time were examined. Comparative effectiveness of treatment was studied in 2 groups similar in all clinical indices. The main (31 people) patients, along with the symptomatic treatment received Wobenzim; control (30 people) - polytherapy (immunocorrecting, antioxidant, antimicrobial agents). As a result of the generally accepted clinical, paraclinical, immunological and biochemical studies conducted during the treatment and at long-term follow-up, it was found that the use of systemic enzyme therapy in this category of patients ensures rapid regression of the main clinical symptoms (on days 6-7), elimination of pathogenetic links of the disease more than in 90% of treated patients and the onset of remission for at least 6-12 months. It is characteristic that during the monotherapy with Wobenzim, positive results of treatment of generalized periodontitis were achieved, similar to those with the use of complex standard therapy, including administration of a number of medications with targeted action on pathogenesis mechanisms of the disease. From the position of evidence-based medicine, the expediency of replacing a broad arsenal of medicines in the complex treatment of generalized periodontitis with certain pharmacological preparations with a systemic effect is justified.